Comparing the current results to its competitors, Calidi Biotherapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 2.35 %, recorded in the same quarter.
Calidi Biotherapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the pharmaceutical and biotechnology sectors, focusing on the development of immune-oncology therapies for cancer, including viral immunotherapies. Its competitors include large pharmaceutical and biotechnology firms such as AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Inc., Merck & Co., Novartis, Pfizer, and Genentech, Inc. Additional competitors developing viral immunotherapies include Oncorus, Inc., Replimune Group, Inc., Amgen Inc., ImmVira Co., Ltd., IconOVir Bio, Inc., Candel Therapeutics, Inc., CG Oncology, Inc., Genelux Corporation, Imugene Limited, Viromissile, Oncolytics Biotech Inc., and FerGene, Inc. The competitive landscape also encompasses academic institutions, government agencies, and other research organizations. Many competitors possess greater financial resources and expertise. Industry consolidation through mergers and acquisitions may concentrate resources among fewer entities. Smaller or early-stage companies may also present significant competition, particularly through collaborations. Competitors also vie for personnel recruitment, clinical trial site establishment, subject enrollment, and acquisition of complementary technologies. The company’s commercial opportunities may be limited if competitors develop safer or more effective products.
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
Candel Therapeutics Inc's business model is centered around developing and commercializing advanced biotherapeutics for the treatment of cancer. They aim to leverage their proprietary oncolytic viral immunotherapy technology to deliver targeted therapies that stimulate the patient's immune system to attack and eliminate tumors. Through partnerships and collaborations, they seek to expand their reach and accelerate the development and delivery of innovative treatments.
Cullinan Oncology Inc's business model focuses on developing innovative cancer treatments by identifying and acquiring promising drug candidates through collaborations and partnerships with academic institutions and biotechnology companies. They prioritize the advancement of these therapies towards clinical trials and commercialization, aiming to address unmet medical needs in the field of oncology.
Compass Therapeutics Inc operates as a biotechnology company focused on discovering and developing novel antibody therapeutics for the treatment of cancer and autoimmune diseases. Their business model revolves around leveraging their proprietary Targeted Immunomodulation platform to identify and advance multiple antibody candidates through preclinical and clinical development stages.
Sources:
Calidi Biotherapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Calidi Biotherapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
